Aisling Capital Management LP - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q2 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.5%.

Quarter-by-quarter ownership
Aisling Capital Management LP ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q2 2024$153,705,606
-18.1%
6,068,1250.0%66.52%
+4.8%
Q1 2024$187,626,425
-23.4%
6,068,1250.0%63.50%
-13.1%
Q4 2023$244,970,206
+53.1%
6,068,1250.0%73.07%
+10.8%
Q3 2023$160,016,456
+53.3%
6,068,1250.0%65.94%
+29.0%
Q2 2023$104,371,750
+3.7%
6,068,1250.0%51.13%
+5.6%
Q1 2023$100,609,513
+117.6%
6,068,1250.0%48.41%
+58.6%
Q4 2022$46,239,113
-23.3%
6,068,1250.0%30.53%
-23.8%
Q3 2022$60,317,000
+9.5%
6,068,1250.0%40.05%
+1.9%
Q2 2022$55,099,000
-10.5%
6,068,1250.0%39.31%
+18.3%
Q1 2022$61,591,000
-39.1%
6,068,1250.0%33.24%
-6.9%
Q4 2021$101,216,000
-64.4%
6,068,1250.0%35.71%
-37.0%
Q3 2021$284,413,000
-23.1%
6,068,1250.0%56.72%
-4.2%
Q2 2021$369,913,000
-1.0%
6,068,1250.0%59.23%
-12.0%
Q1 2021$373,797,000
+31.8%
6,068,125
+52.1%
67.28%
+38.1%
Q4 2020$283,687,000
+89.5%
3,989,4120.0%48.72%
+1.9%
Q3 2020$149,683,000
+15.1%
3,989,4120.0%47.82%
-3.7%
Q2 2020$130,095,000
+12.4%
3,989,4120.0%49.65%
-1.5%
Q1 2020$115,693,000
-13.9%
3,989,412
+4.0%
50.40%
-2.2%
Q4 2019$134,442,000
+63.3%
3,835,7220.0%51.51%
+20.0%
Q3 2019$82,353,000
-20.4%
3,835,7220.0%42.93%
-2.8%
Q2 2019$103,449,0003,835,72244.18%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q2 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$60,317,00040.05%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$308,746,0006.20%
M28 Capital Management LP 513,300$5,102,0005.33%
GREAT POINT PARTNERS LLC 1,050,000$10,437,0002.51%
Octagon Capital Advisors LP 933,743$9,281,0001.60%
HHLR ADVISORS, LTD. 5,362,014$53,298,0001.40%
VIKING GLOBAL INVESTORS LP 26,620,991$264,613,0001.22%
Cormorant Asset Management, LP 1,469,179$14,604,0001.02%
Fernwood Investment Management, LLC 204,550$2,033,0000.86%
TANG CAPITAL MANAGEMENT LLC 585,424$5,819,0000.71%
View complete list of BRIDGEBIO PHARMA INC shareholders